Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Squalamine Lactate + Verteporfin in Wet AMD
NCT00094120Phase 2Terminated
- Sponsor
- Genaera Corporation
- Start
- Oct 2004
- Primary completion
- Feb 2007
- Modality
- Multivalent & Scaffold-Based Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of squalamine in exudative macular degeneration (4 arms), sponsored by Genaera Corporation. Primary endpoint: Safety and Tolerability at 29 weeks. Started Oct 2004; status: terminated.
02
Drugs
squalamine
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00094120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094120.